MP
TXMD icon

McDonald Partners’s TherapeuticsMD TXMD Stock Holding History

McDonald Partners’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,600
Closed -$49K – 311
2022
Q1 		$49K Buy
+2,600
New +$40.9K 0.01% 305
2021
Q4 		– Sell
-4,520
Closed -$168K – 710
2021
Q3 		$168K Buy
4,520
+800
+22% +$35.5K 0.04% 291
2021
Q2 		$221K Buy
3,720
+520
+16% +$31.5K 0.05% 282
2021
Q1 		$214K Buy
3,200
+1,630
+104% +$128K 0.06% 271
2020
Q4 		$95K Buy
+1,570
New +$107K 0.03% 274

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

McDonald Partners's TXMD Position: Q2 2022 in Review

McDonald Partners sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 2,600 shares — an estimated $49K sold.

McDonald Partners first reported a position in TXMD in Q4 2020 and held it in 5 quarters. The position peaked at $221K in Q2 2021. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • McDonald Partners reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • McDonald Partners sold 2,600 TherapeuticsMD shares in Q2 2022, an estimated $49K.
  • McDonald Partners first reported a position in TherapeuticsMD in Q4 2020 and held it in 5 quarters.
  • McDonald Partners's TherapeuticsMD position peaked at $221K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on McDonald Partners's 13F filing for Q2 2022, filed 25 Jul 2022.